Skip to main content

SASB

TOPIC ACCOUNTING METRIC CODE NOTE
Safety of Clinical Trial Participants Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials HC-BP-210a.1
Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI) HC-BP-210a.2
Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries HC-BP-210a.3
  • No business in developing countries
Access to Medicines Description of actions and initiatives to promote access to healthcare products for priority diseases and in priority countries as defined by the Access to Medicine Index HC-BP-240a.1
  • No business in priority countries
List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP) HC-BP-240a.2
Afordability & Pricing Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period HC-BP-240b.1
  • Not disclosed
Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year HC-BP-240b.2
  • No business in U.S.
Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year HC-BP-240b.3
  • Product: LUTEUM (1)NHI Price: 541.90 (2)Net Price: Not disclosed

Drug Safety List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts for Human Medical Products database HC-BP-250a.1
Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System HC-BP-250a.2
Number of recalls issued, total units recalled HC-BP-250a.3
Total amount of product accepted for take-back, reuse, or disposal HC-BP-250a.4
Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type HC-BP-250a.5
Counterfeit Drugs Description of methods and technologies used to maintain trace ability of products throughout the supply chain and prevent counterfeiting HC-BP-260a.1
Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products HC-BP-260a.2
Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products HC-BP-260a.3
Ethical Marketing Total amount of monetary losses as a result of legal proceedings associated with false marketing claims HC-BP-270a.1
Description of code of ethics governing promotion of off-label use of products HC-BP-270a.2
Employee Recruitment, Development & Retention Discussion of talent recruitment and retention efforts for scientists and research and development personnel HC-BP-330a.1
  • Not disclosed
(1) Voluntary and (2) involuntary turn over rate for: (a) executives/seniormanagers, (b) mid-level managers, (c) professionals, and (d) all others HC-BP-330a.2
SupplyChain Management Percentage of (1) entity's facilities and (2) Tier 1 suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients HC-BP-430a.1
Business Ethics Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery HC-BP-510a.1
Description of code of ethics governing interactions with health care professionals HC-BP-510a.2
ACTIVITY METRIC CODE NOTE
Number of patients treated HC-BP-000.A
Number of drugs (1) in portfolio and (2) in research and development (Phases1-3) HC-BP-000.B